Syntax Research Inc. Sells 2,772 Shares of Thermo Fisher Scientific Inc. $TMO

Syntax Research Inc. decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 55.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,210 shares of the medical research company’s stock after selling 2,772 shares during the quarter. Thermo Fisher Scientific comprises approximately 0.8% of Syntax Research Inc.’s investment portfolio, making the stock its 19th biggest holding. Syntax Research Inc.’s holdings in Thermo Fisher Scientific were worth $1,108,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. J. Stern & Co. LLP boosted its position in shares of Thermo Fisher Scientific by 58,006.4% during the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after purchasing an additional 31,455,105 shares in the last quarter. BlackRock Inc. acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth $15,501,867,000. Corient Private Wealth LP bought a new position in Thermo Fisher Scientific during the second quarter worth about $382,547,000. Norges Bank acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at about $3,072,744,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Thermo Fisher Scientific in the second quarter worth about $1,974,561,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Stifel Nicolaus set a $650.00 price objective on Thermo Fisher Scientific in a report on Wednesday, August 5th. Wolfe Research began coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 target price for the company. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. CLSA assumed coverage on shares of Thermo Fisher Scientific in a report on Thursday. They set an “outperform” rating and a C$748.00 price objective on the stock. Finally, Evercore set a $570.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $619.41.

Thermo Fisher Scientific Trading Up 1.7%

NYSE TMO opened at $618.91 on Friday. The stock has a market capitalization of $228.84 billion, a price-to-earnings ratio of 33.29, a PEG ratio of 2.54 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $647.00. The stock’s 50 day moving average price is $568.92 and its two-hundred day moving average price is $514.41. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same period last year, the company earned $4.28 earnings per share. The firm’s revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

Insider Buying and Selling

In related news, CAO Joseph Holmes sold 420 shares of the company’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the sale, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Lisa Britt sold 11,440 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the transaction, the vice president directly owned 14,784 shares of the company’s stock, valued at $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 73,768 shares of company stock worth $44,122,820 in the last three months. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.